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Background: Depression is common in diabetes and associated with hyperglycemia, diabetes related
complications and mortality. No single intervention has been identified that consistently leads to simultaneous
improvement of depression and glycemic control. Our aim is to analyze the efficacy of a diabetes-specific cognitive
behavioral group therapy (CBT) compared to sertraline (SER) in adults with depression and poorly controlled
diabetes.
Methods/Design: This study is a multi-center parallel arm randomized controlled trial currently in its data analysis
phase. We included 251 patients in 70 secondary care centers across Germany. Key inclusion criteria were: type 1 or
2 diabetes, major depression (diagnosed with the Structured Clinical Interview for DSM-IV, SCID) and hemoglobin
A1C >7.5% despite current insulin therapy. During the initial phase, patients received either 50–200 mg/d sertraline
or 10 CBT sessions aiming at the remission of depression and enhanced adherence to diabetes treatment and
coping with diabetes. Both groups received diabetes treatment as usual. After 12 weeks of this initial open-label
therapy, only the treatment-responders (50% depression symptoms reduction, Hamilton Depression Rating Scale,
17-item version [HAMD]) were included in the subsequent one year study phase and represented the primary
analysis population. CBT-responders received no further treatment, while SER-responders obtained a continuous,
flexible-dose SER regimen as relapse prevention. Adherence to treatment was analyzed using therapeutic drug
monitoring (measurement of sertraline and N-desmethylsertraline concentrations in blood serum) and by counting
the numbers of CBT sessions received. Outcome assessments were conducted by trained psychologists blinded to
group assignment. Group differences in HbA1c (primary outcome) and depression (HAMD, secondary outcome)
between 1-year follow-up and baseline will be analyzed by ANCOVA controlling for baseline values. As primary
hypothesis we expect that CBT leads to significantly greater improvement of glycemic control in the one year
follow-up in treatment responders of the short term phase.
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Discussion: The DAD study is the first randomized controlled trial comparing antidepressants to a psychological
treatment in diabetes patients with depression.
The study is investigator initiated and was supported by the ‘Förderprogramm Klinische Studien (Clinical Trials)’ and the
‘Competence Network for Diabetes mellitus’ funded by the Federal Ministry of Education and Research (FKZ 01KG0505).
Trial registration: Current controlled trials ISRCTN89333241.Background
Diabetes and depression
Diabetes mellitus is a highly prevalent chronic disease
affecting approximately 9 to 10% of the global adult popu-
lation [1]. Based on estimates of the International Diabetes
Federation there were 366 million people with diabetes in
2011, and this rate is expected to rise to 552 million by
2030 [2]. Diabetes is a major cause of morbidity and mor-
tality [3] and extremely costly in economic terms [4].
People with diabetes are at twice the risk of developing de-
pression compared with control groups without diabetes.
Accordingly, 9% of patients with diabetes meet the criteria
for major depression (controls: 5%) and approximately
25% of patients with diabetes mellitus are suffering from
single or multiple depression symptoms (controls: 14%),
which includes major depression as well as subclinical de-
pression [5].
There is a strong body of evidence for multiple ad-
verse interactions between diabetes and depression.
Overall, the comorbidity of depression and diabetes is
associated with adverse diabetes outcomes, especially
higher hemoglobin A1c (HbA1c) levels [6], micro- and
macrovascular complications [7], mortality [8,9], greater
diabetes-related symptom burden [10], increased func-
tional impairment, and poorer adherence to diet, exer-
cise, and diabetes self-management [11]. In addition,
coexisting depression in people with diabetes is associ-
ated with poorer mental and physical quality of life [12]
and markedly increased health care costs [13,14].
Treatment of depression in diabetes
According to the above mentioned results, the treatment of
comorbid depression is considered as essential for the clin-
ical care of diabetes patients [15]. When treating depressed
diabetes patients, there are two major treatment goals:
(1) remission or improvement of depression, and
(2) improvement of the often poor glycemic control. The
second goal is generally considered as fundamental to
the management of diabetes, in order to prevent or
delay long-term complications [16].
Up to now, three different approaches to treat depression
in diabetes have been evaluated in randomized controlled
trials (RCT): Antidepressant medication, psychologicaltreatments (e. g. cognitive behavioral therapy, counseling,
problem solving training) and a flexible combination of
both in stepped care approaches. In 2010, treatment ef-
fects were summarized in a meta-analysis of 14 RCTs [17]
and in 2012 in a systematic Cochrane review including 19
RCTs [18].
As a result of both analyses there is growing evi-
dence that depression can be treated with moderate
success in patients with diabetes using either psycho-
logical, pharmacological and stepped care interventions
(combined effect sizes [ES] d −0.51; 95% confidence
interval [CI] -0.63 to −0.39). With regard to the goal of
improved glycemic control the results are controver-
sial: while the meta-analysis calculated small combined
effect sizes for all treatments taken together (ES d −0.27;
95% Kl −0.40 to −0.15) [17], the Cochrane review con-
cluded that ‘glycemic control improved moderately in
pharmacological trials, while the evidence is inconclusive
for psychological intervention. Overall, the evidence is
sparse and inconclusive due to several low-quality trials
with substantial risk of bias and the heterogeneity of exam-
ined populations and interventions’ [18].
In sum, despite the relevance of the topic and the in-
creased research activity over the last two decades, there is
still a considerable lack of knowledge when facing the ques-
tion to identify the most effective treatment for depression
in diabetes. Especially, due to the combination of interven-
tions in the collaborative care trials with sound metho-
dology, e.g. [19-21], it is impossible to identify the effective
components of compound treatments or to evaluate the
superiority of one treatment (e.g. antidepressants) above
another (e.g. cognitive behavioral therapy, problem solving
training). Finally, there exist no published data to identify
the best treatments among effective treatments; and more
specifically, to our knowledge no trial was conducted com-
paring pharmacological to psychological interventions in
patients with diabetes and comorbid depression.
To address this lack of knowledge we conducted the
Diabetes and Depression Study (DAD study), a random-
ized, multicenter, controlled trial comparing a diabetes-
specific CBT to SER in poorly controlled diabetes patients
with major depression.
Current status of the trial
Data analysis phase.
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Primary objective
The aim of the planned study is to evaluate the efficacy
of a diabetes-specific CBT combined with diabetes edu-
cation versus a continuous treatment with SSRI (SER)
combined with diabetes education in high-risk patients
with poorly controlled insulin-treated type 1 or type 2
diabetes mellitus and depression.
Principal research question
Does a diabetes-specific psychotherapy (CBT) or anti-
depressant medication (SER) improve long-term glycemic
control in patients with poorly controlled diabetes and
depression?
Primary hypothesis
CBT leads to a better improvement of glycemic control
when compared with SER at the one-year follow-up in pa-
tients who initially responded to short-term therapy (CBT
or SER) with regard to improvement in depression.
Primary endpoint: Change of glycemic control (hemo-
globin A1C).
Secondary objectives
To provide clear scientific evidence whether the two
most widely established treatments (SSRI and CBT) for
patients with depression but without additional somatic
diseases can be applied to high-risk patients with poor
metabolic control of insulin-treated diabetes and comor-
bid depression.
Secondary hypothesis
CBT and SER are both effective in terms of remission of
depression after 12 weeks in an open label trial as well
as at the one-year follow-up.
Secondary endpoints
(a) remission of depression: no longer fulfilling the
DSM-IV-TR criteria for depression according to
the Structured Clinical Interview for DSM-IV,
SCID [22], and depression score according to the
HAMD –Interview [23] < = 7;
(b) improvement of depression (>/= 50% reduction of
(HAMD-baseline score);
(c) improved generic HRQoL, per SF-36 [24]; and
(d) decreased problems in daily living with diabetes,
per PAID [25].
Methods/Design
Study design, setting, recruitment and procedures
This trial is a prospective, randomized, multicenter, par-
allel arm controlled clinical trial that involved the twotreatment conditions CBT vs. SER in a parallel group de-
sign (see Figure 1).
The recruitment of the patients took place between
April 2006 and May 2009 in 70 trial centers of out-
patient secondary care (specialized diabetological prac-
tices and ambulatory care health services in clinics)
located in different parts of Germany (predominantly in
the Rhine-Main area, Ruhr area and Düsseldorf/Köln).
Four coordinating trial centers (Bochum/Dortmund,
Mainz, Düsseldorf/Köln and Bad Mergentheim) orga-
nized the recruitment activities in the diabetological
trial centers located in their vicinity. All insulin-treated
outpatients with diagnosed type 1 or type 2 diabetes
registered in the respective diabetological trial centers
within the age range of 21 to 69 years and with an
HbA1c value >7.5% received a letter by their diabetol-
ogist with a patient information leaflet about the trial.
They were invited to participate and informed that they
would receive a telephone call by a research assistant.
During the telephone call, the research assistant pro-
vided further information about the trial and asked
consent for the baseline assessment, which then took
place in one of the diabetological trial centers. After
having provided written informed consent, medical eli-
gibility criteria of a patient was checked by his or her
diabetologist.
Psychological eligibility criteria such as depression,
excluded history of schizophrenia etc. were assessed
by clinical psychologists who had undergone an inten-
sive standardized training provided by one of the au-
thors (MJM). Depression was measured in a two stage
screening-procedure starting with a questionnaire-
based screening (German version [26] of the Centre
for Epidemiologic Studies Depression Scale (CES-D)
[27], followed by the Structured Clinical Interview
for DSM-IV (SCID) [22] for those patients who were
screened positive. Severity of depression was measured
with the HAMD. To assure the quality of the HAMD
training we first established an expert standard rating
(which consisted of an agreement of three highly expe-
rienced raters). During the training we computed
chance-corrected coefficients (weighted κ) of rating
agreement with the expert standards for the single
items and the total score of the HAMD. Item ratings
within the accepted range of the standard rating ± 1
obtained a full credit of 1 and ratings outside the
accepted range a weight of 0 (no credit). Values of κw>
0.40 denote acceptable chance-corrected agreement, co-
efficients κw > 0.80 indicate almost perfect strength of
agreement [28]. High interrater reliability (κ>0.80) was
achieved for most of the HAMD items and excellent
interrater reliability was demonstrated for the total
score (κw 0.96 ± 0.08), thus indicating that the
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Figure 1 Design of the DAD study.
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iables were assessed using psychometric questionnaires
(described in the ‘Measures’ section).
Patients meeting all eligibility criteria (see ‘Eligibility
criteria’ section) were offered a short structured diabetes
education (2 × 3 hours) by trained diabetes educators as
an update to ensure sufficient diabetes knowledge in all
trial participants (see ‘Diabetes education’ section). All
patients completing the diabetes education program
were allocated randomly to either 10 sessions of group
CBT or an algorithm based SER- treatment with 50 to
200 mg/day according to treatment response and side
effects (see ‘Randomization and blinding’ section and
‘Interventions’ section). Diabetes treatment was not part
of the trial protocol and was continued ‘as usual’.
The trial consisted of a 12-week open label therapy
short-term phase. Treatment responders of both groups
(≥ 50% reduction of the HAMD baseline score or
HAMD post-treatment score ≤ 7) were included in a 12-
month long-term phase. These patients constituted the
intention-to-treat (ITT) population. Non-responders of
the short-term phase were excluded from the treatment
protocol and referred to the best available treatmentusing standard medical care. The general recommenda-
tion to the treating physicians was to give SER or other
medication to CBT-non-responders and to give CBT or
other medication to SER- non-responders.
All patients entering the long-term phase received on-
going diabetological treatment as usual by their treating
physicians in the diabetological trial center at 3-month in-
tervals during the following 12 months. SER-responders
received a continuous SER- treatment as relapse preven-
tion. CBT responders did not receive further treatment
but were encouraged to work with a patients manual in
the sense of a bibliotherapy [29] during the one year
follow-up phase. The difference in the active treatment
duration between both interventions corresponds to usual
clinical practice and thus assure external validity. Gene-
rally, group CBT is offered for a limited period of time
assuming that ‘carry over’ effects will stabilise the results
[30,31], while SER in patients responding to the treatment
is given for a longer period of time as relapse prevention
(see also German National Disease Management Guide-
lines [32]). In order to control for the amount of physician
contact patients of both groups underwent the same num-
ber of visits. During the visits, the CES-D questionnaire
Table 1 Eligibility criteria for the DAD study
Inclusion criteria
- Type 1 or type 2 diabetes mellitus diagnosed at least 12 months
before entering the trial
- Insulin treatment for at least the preceding 6 months
- 21 to 69 years of age (amended to protocol in August 2006) Initially: 21
to 65 years of age
- Poor glycemic control: HbA1c level > 7.5% within the nine preceding
months, at least 3 months before screening and again in screening
measurement (amended to protocol in August 2006/April 2007) Initially:
HbA1c value > 8% twice between the preceding 9 months
- Current major depression (DSM-IV-TR criteria)
- Residence near the coordination institution where CBT treatment will
take place (<1 hour access)
- Ability of subject to understand character and individual
consequences of clinical trial
- Women with child bearing potential in the sertraline group: Women
will be informed that women with childbearing potential in the
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patients treated with SER, additional analyses of SER and
its major metabolite (N-desmethylsertraline) in blood
serum were performed as measurement of treatment ad-
herence (see ‘Assessment of adherence’ section).
Drug analyses were performed as described previously
using a validated high performance liquid chromato-
graphic method with column switching and spectrophoto-
metric detection [33]. Intra- and interassay variabilities
were below 10%.
At the 12-month follow-up, both treatment groups were
re-examined regarding the primary outcome variable
HbA1C. In addition, SCID and HAMD interviews as well
as psychometric questionnaires were administered among
others to evaluate the treatment effects regarding depre-
ssion, health-related quality of life, and disease-specific
burdens.sertraline group should use highly effective birth control methods (e.g.
combined oral contraceptives, implants)
- Written informed consent
Exclusion criteria
- Clinically significant suicide risk or history of attempted suicide in the
past 12 months (amended to protocol in April 2007) Initially: Clinically
significant suicide risk or history of attempted suicide
- History of schizophrenia or psychotic symptoms
- Bipolar disorder
- Organic brain syndrome or dementia
- Alcohol or substance abuse or dependence in the past 6 months
- Insufficient ability to understand German
- Psychotherapy in the preceding 3 months
- Pregnant or lactating patient
- History of convulsion or seizure disorder
- Current use of mood stabilizers, neuroleptics, antidepressants, or
benzodiazepines except for
(1) continuation of unchangeable stable amitriptyline given to
treat painful diabetic neuropathy up to 50 mg per day
(2) short-term use of benzodiazepines (less than 2 weeks)
(3) low-potency neuroleptics in low doses, i.e. less than 300 mg
chlorpromazine dose equivalents/day (amended to protocol 08/2006)
Continuation of stable treatment with thyroid hormones is also
permitted
- Significant liver enzyme elevations: SGOT (aspartate aminotransferase,
AST) or SGPT (alanine aminotransferase, ALT) above 3-fold of normal
upper limits or significant other laboratory findings (physician’s decision)
- Pre-treatment with reversible MAO inhibitors within the past 2 weeks
or current, unchangeable co-medication with tryptophan,
fenfluramine, or serotonin agonists (triptans)
- History of hypersensitivity to the investigational medicinal product or to
any drug with similar chemical structure or to any excipient present in
the pharmaceutical form of the investigational medicinal product
- Participation in other clinical trials and observation period of
competing trials, respectively
Note: All changes in eligibility criteria were amended to the protocol during
the trial and before breaking of the blinding.Eligibility criteria (inclusion and exclusion criteria)
Initially, all insulin-treated diabetes patients within the
age range of 21 to 65 years, with an HbA1c value > 8%
and major depression according to DSM-IV criteria were
to be included, provided that they also met the other in-
clusion and exclusion criteria. Two eligibility criteria and
two exclusion criteria were revised and amended to the
protocol in August 2006 and April 2007. The age range
was changed from originally 21–65 years to 21–69 years
to increase the number of eligible subjects. The inclu-
sion criterion of HbA1c > 8% was changed into >7.5%,
because we faced serious difficulties to find poorly
controlled patients in the secondary care recruitment
centers. As an explanation for this unexpected situation
we think that the successful introduction of disease
management programs (DMP) in Germany at that time
might have led to a decrease in HbA1c values in patients
with type 2 diabetes [34,35]. Moreover, we assumed that
patients with very poorly controlled type 2 diabetes
would have still been treated in primary care settings
not participating in the DMPs.
To enhance comparability with international studies
and to prevent a selection bias, our independent scien-
tific advisory board (see ‘Quality assurance’ section)
recommended excluding patients only in case of cli-
nically significant suicide risk or history of attempted
suicide in the past 12 months. The exclusion criterion
regarding the current use of psychotropic drugs was
modified to allow the inclusion of patients treated with
low potency neuroleptics in low doses (less than 300 mg
chlorpromazine dose equivalents per day), as these
drugs are often used to treat sleeping disorders and rest-
lessness in diabetes patients, particularly in those suffer-
ing from diabetic neuropathy. Detailed inclusion and
exclusion criteria are listed in Table 1.
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Randomization
Patients were randomized using block randomization to
ensure equal group sizes. For each coordinating institu-
tion, a separate randomization procedure stratified by
type of diabetes was performed to ensure balanced treat-
ment groups across and within coordinating institutions.
Randomization lists were generated by the Interdiscip-
linary Center for Clinical Trials Mainz (IZKS), University
Medical Center Mainz by means of a computer program.
These randomization lists included the patient identifi-
cation number (SUBJID) used for identifying all data
collected from the subject during the study and for
the treatment allocation. The randomization lists were
maintained by the IZKS. The treatment allocation at the
coordinating institutions was performed using FAX
randomization. After checking subject’s eligibility, the
investigator faxed a randomization request form to the
IZKS randomization center. This form included infor-
mation on the patient’s sex, year of birth and type of
diabetes. The IZKS randomization center entered the
SUBJID and treatment allocation on the request form
and faxed the form back to the investigator’s site.Blinding
In the DAD study, psychotherapy (CBT) was compared
to medication and there was no placebo condition. Thus,
a blinding of patients or health care providers was not
possible. However, a blinding of all members of the re-
search team involved in the assessment of outcomes was
carried out.Interventions
Diabetes education
Given the poor glycemic control of the patients and consid-
ering that most patients treated with insulin had likely
undergone diabetes education previously (according to the
German evidence based guidelines that were in force at the
time of the patient recruitment [36]), a short diabetes edu-
cation program was offered to all patients as an update. Pa-
tients received structured diabetes education (2 × 3 hours)
before randomization. The program included the following
modules: (1) insulin treatment; (2) self-monitoring with
regard to diabetes-relevant behavioral strategies (e.g., nutri-
tion, physical activity, foot care); (3) the recognition, treat-
ment, and prevention of acute complications; and (4) risk
factors (e.g., hyperlipidemia, arterial hypertension, smoking)
for macroangiopathic diabetes-related illnesses. This dia-
betes education was offered by trained diabetes educators
using a manual that was established for the DAD study (see
Additional file 1 ‘Structured diabetes education manual for
diabetes educators’ in German).Diabetes specific cognitive behavioral group therapy (CBT)
CBT was offered as manualized diabetes-specific treat-
ment delivered by clinical psychologist who had under-
gone a systematic training regarding the manual. Each
session was videotaped and a random sample of 13% of
the sessions (N = 32 sessions) was used in order to con-
tinuously evaluate and ensure the adherence to the man-
ual and to give continuous supervision by one of the
authors, who is a CBT trainer and supervisor (FP). We
additionally developed and evaluated a rating system to
assess the expertise of the therapists with acceptable to
good interrater reliability (intraclass correlation coeffi-
cient, ICC 0.73 to 0.96). A second rating system to as-
sess adherence to the CBT manual was also developed
and showed good to excellent interrater reliability (coef-
ficient 0.74 to 1.0) (details of the rating systems will be
published separately).
CBT was delivered in groups of 4 to 10 patients per
group in an outpatient setting within a 12–week time
period. This treatment consisted of 10 sessions (20 hours)
using a manualized semi-structured CBT for depression,
including different diabetes-specific aspects in order
to improve adherence to diabetes treatment and coping
with diabetes (see Additional file 2 ‘Diabetes-specific CBT
manual for therapists’, in German). The psychoeducation
section (sessions 1–3) included information about the as-
sociation of mood and activities and the development and
maintenance of depression. In addition, participants
learned about the link between diabetes and mood and
ways to influence impaired mood with cognitive tech-
niques. Furthermore, participants were encouraged to dis-
cuss diabetes-specific goals such as HbA1c target values
with their diabetologists and to specify behavioral goals in
order to improve their glycemic control (see Additional
file 3 ‘Working sheet for diabetologists and patients: strat-
egies to improve glycemic control’, in German). Individual
goal achievement was assessed in sessions six and ten and
possible barriers to the goal attainment were identified
and modified if possible. To help patients identifying and
reducing perceived barriers to various aspects of self-
management and to enhance coping skills, the problem-
solving section (sessions 4–7) covered cognitive and be-
havioral techniques (e.g. cognitive restructuring, stress
management). Fear of diabetes complications and appro-
priate coping-strategies were topics of further sessions. In
the last session participants learned how to prevent and
cope with depression relapse. Each participant received a
patient workbook including theoretical background, work-
sheets, and exercises for each session (see Additional file 4
‘working book for patients of the diabetes-specific CBT
group’, in German). Patients were encouraged to continue
working with the book after the end of the short-term
phase to stabilize and generalize the improvement in the
sense of a bibliotherapy [29].
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SER treatment was started at a dose of 50 mg/day in the
morning following an algorithm which is described in
Table 2. If no clinical response was achieved within 2–
4 weeks, the dose could be raised to 100 mg/day in the
morning. Further dose escalation up to 200 mg per day
was possible with changes not exceeding 50 mg/ week.
Recommendation for dose changes according to re-
sponse and side effects were based on the Clinical Glo-
bal Impression Rating (CGI) [37] and the UKU side
effects rating scale [38]. Patients and clinician’s ratings
of side effects and treatment response as well as the
current course of treatment (duration of treatment and
changes) were taken into account. Optional supplemen-
tary visits and telephone contact were possible at any
time. Additionally one of the authors, a psychiatrist and
clinical psychologist (MJM), offered advice to the
treating diabetologists providing a psychiatric hotline if
questions regarding the medication occurred. During the
long-term phase of the trial SER responders received a
continuous SER treatment as relapse prevention.
Measures
Outcome measures were assessed at baseline, at the end
of the short-term phase (12 weeks), at months 6, 9, 12
during the long-term phase and at the end of the long-
term phase (15 months). For patients randomized to
SER treatment, additional assessments were scheduled at
week 2 and 8 during the short term phase to deliver
medication and monitor the response and side-effects.
At week 8 and 12 SER and desmethylsertraline blood
levels were assessed. Figure 2 summarizes all medical
and psychosocial variables, which were assessed in the
current trial, by time of data collection. Adverse events
were monitored and recorded continuously during the
trial (see Additional file 5 ‘Safety manual’, in German;
and ‘Definitions and assessment of adverse events’).
Primary outcome
Initially, the primary outcome was ‘improvement of gly-
cemic control’, defined as a decrease of at least 1% in
HbA1c value (yes/no) from baseline to the end of theTable 2 Algorithm for the sertraline treatment in the DAD tri
No improvement (< 20%)
(CGI = 0)
UKU side effects 50 mg 75-175 mg
Absent (0) mild (1) ⇔ or ⇧ ⇔ or ⇧
Moderate (2) severe (3) x ⇩
Note: Moderate/severe side effects are side effects that impairs the patient ⇧ Incre
wait and see without change in dose (generally up to 4–6 weeks), x = consult psyc
medication without further consultation. The decisions should always be based on
treatment response assessed by the physician using the CGI rating, and treatment e
be made by the treating physician based on the algorithm recommendations and tlong-term phase. Due to an advice of the advisory board,
the analysis of the primary outcome parameter was
changed and amended to the protocol in November 2008
into ‘change of glycemic control’, defined as the difference
in HbA1c value from baseline to the end of the long-term
phase. By changing the dichotomous endpoint into a con-
tinuous endpoint, the statistical power of the trial could
be enhanced and the planned number of trial subjects had
to be reduced (see ‘Sample size calculation’ section).
Secondary outcomes
Secondary outcomes were ‘remission of depression’; i.e.
not fulfilling the DSM-IV-TR criteria for depression
according to the SCID and HAMD scores ≤ 7, ‘improve-
ment of depression’, i.e. a reduction of the HAMD score
from baseline to the end of trial by at least 50%, ‘im-
provement of health-related quality of life (HRQoL)’, i.e.
change in generic HRQoL from baseline to end of trial
as assessed per SF-36 mental and physical component
scores [24], and ‘improvement of diabetes related stress’,
from baseline to end of trial as measured per PAID [39].
As amended to the protocol, the previous primary out-
come (improvement of glycemic control of at least 1% in
HbA1c value from baseline to the end of the long-term
phase) was assessed as a secondary outcome.
Other psychometric measures
A number of other psychometric variables were investi-
gated and measured with validated German questionnaires
or German versions of internationally validated question-
naires at baseline, after the end of the short-term phase
and in the one year follow-up: Diabetes knowledge was
measured with a Diabetes Knowledge Questionnaire for
Type 1 (Diabetes-Wissens-Test Typ-I -, DWT-I) [40] and
Type 2 Diabetes (Diabetes-Wissens-Test Typ-II, DWT-II)
[41], diabetes self-care by the Summary of diabetes self-
care activities measure (SDSCA) [42], diabetes-specific
locus of control by the IPC-Diabetes-Questionnaire (IPC-
D1) [43] and psychological barriers to insulin therapy by
the Barriers to Insulin Therapy Questionnaire (BIT) [44].
Coping was assessed using the Freiburger Coping with Ill-
ness Questionnaire (15-item version, FKV-15) [45], self-al
At least minimal improvement
(CGI 1 to 3)
200 mg 50 mg 75-175 mg 200 mg
⇔ or x ⇔ or ⇧ ⇔ or ⇧ ⇔
⇩ x ⇩ ⇩
ase dose in 25-50 mg/day steps, ⇩ reduce dose in 25-100 mg/day steps, ⇔
hiatric hotline and decide how to procede afterwards or discontinue the
the tolerability as assessed by the treating physician with the UKU, the
ffects and tolerability as judged by the patient. In the end, the decision has to
he judgement of the patients.






Planned Study Day -42 to -16 -15 - 14 to -1 1 15 56 83 84 175 267 358 449 450
Visit Screening P0 S1 S2* S3 S4 P1 L1 L2 L3 L4 P2
Screening information, informed consent D
Screening, inclusion/exclusion criteria D
Blood-sample (HbA1c) D D D D D D D
Blood-sample (liver enzymes, other 
endocr. parameters) D D D D
Treatment preference P
CES-D questionnaire D D D D D D D
Diagnosis information, informed consent D
Other questionnaires P P P
Hamilton Rating Scale (HAMD-17) P P P
SCID-Interview P P
Review mental disorder related 
inclusion/exclusion criteria P
Treatment information, informed consent P D
Randomisation D
CBT group: Cognitive behavioural 
therapy
10 sessions P
Sertraline group: Delivery of medication D D D D D D D D
Sertraline group: Blood-sample (plasma 
concentrations of sertraline) D D D D D D
Diabetological treatment as usual D D D D D D D
Dose adjustment insulin/sertraline optional supplementary visits in case of problems with diabetological treatment or side-effects of sertraline D
Recording and monitoring of adverse 
events continuously D, P
Recording of concomitant medication continuously D





















Figure 2 Measurements in the DAD study. Note: P = visit to the coordinating institutions were questionnaire and interviews will be
administered by members of the research team (research assistants, psychologists); D = visit to the treating physician or research assistants in the
diabetologic trial centres. *Visit S2 is optional by telefone or personally.
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hopelessness by the Hopelessness Scale (H-Scale) [47];
incongruence by Inkongruence Questionnaire (K-INK)
[48], childhood traumata by Childhood Trauma Question-
naire (CTQ) [49,50] psychological problems and symptoms
of psychopathology by the Short-Form of the Symptom
Checklist SCL-90-R [51] (German version, SCL-K-9) [52];
and social support by the Questionnaire of perceived fam-
ily support and communication (PFUK) [53].
Assessment of treatment preference
Treatment preference was assessed as follows: ‘If you were
depressed and you could choose between two equally ef-
fective treatments that might cure your depression, which
ONE would you choose?’
(1) Free medication daily for 15 months (no or only
minor side effects to be expected);
(2) 10 sessions (2 hours each, within a 3–month time
period) of group psychotherapy with a maximum
of 10 group members, with a focus on depression
and diabetes-related problems;
(3) I do not prefere either treatment.Assessment of the patient- and therapist perspectives of the
(CBT) sessions
Each CBT session was rated by patients and therapists
assessing the perceived personal involvement and confi-
dence regarding the group therapy. The group therapists
and the supervisor received the results as continuous
feedback before the next session in order to reflect and
if necessary to improve the therapeutic strategy in the
respective group. The questionnaire was validated within
the DAD study with good psychometric results [54].
Assessment of adherence to treatment
Adherence to treatment was defined by measuring the re-
ceived therapy 'dose' (see Table 3 for an overview about
the definition of adherence to CBT and SER treatment).
Adherence to CBT was assessed by the number of
attended CBT-sessions. As there exists no established
measure of adherence for psychotherapy, in the current
trial sufficient adherence to CBT was defined as partici-
pation in at least eight out of ten sessions.
Adherence to SER treatment was assessed by re-
peated measures of serum SER concentrations and the
ratio of metabolite to parent compound, i.e. ratio of N-
Table 3 Definition of treatment adherence in the CBT and sertraline treatment groups
Adherence categories CBT Sertraline (randomized sample) Sertraline (ITT sample)
Adherent Participation in≥ 8 sessions of CBT 2 measures SER and corresponding
ratio DSER:SER in target range
≥ 5 measures SER and corresponding
ratio DSER:SER in target range
Partially non-adherent Participation in 1–7 sessions of CBT 1 measures SER and corresponding
ratio DSER:SER in target range
1-4 measures SER and corresponding
ratio DSER:SER in target range
Non-adherent No participation in any session of CBT no measures SER and corresponding
ratio DSER:SER in target range
no measures SER and corresponding
ratio DSER:SER in target range
Note: SER: blood concentration of sertraline. DSER:SER: ratio of desmethylsertraline to sertraline concentrations. Target ranges of SER were defined as
concentrations between 10–100 ng/ml [55]. Target ranges of DSER:SER were defined as 0.85–4.25, corresponding to the mean ± 2 standard deviations (M = 2.55,
SD = 0.85) derived from 348 samples by Reis et al. [51].
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Reis and colleagues [56]. As patients identified as treat-
ment non-responders after the end of the short-term
phase were excluded from the treatment protocol, SER
adherence was evaluated separately for randomized
patients and ITT patients. For randomized patients, ad-
herence was assessed based on SER concentrations and
DSER: SER measured at week 8 and 12. For ITT pa-
tients, adherence was assessed based on SER concentra-
tions and DSER: SER measured at week 8, 12, 24, 36, 48
and 60. Notwithstanding initial planning and Thera-
peutic Drug Monitoring (TDM) guidelines [57], which
recommend concentrations between 10–50 ng/ml, target
ranges of SER were defined as concentrations between
10–100 ng/ml, as up to 100 ng/ml no severe adverse ef-
fects are to be expected. Furthermore, it has to be taken
into account that the trial participants suffer from
chronic disease and receive concomitant medications,
which affect drug metabolism potentially resulting in
higher serum concentrations [56]. To avoid biased ad-
herence ratings, patients discontinuing the trial partici-
pation due to severe adverse events or discontinuing
SER intake because of their physician’s recommendation,
were excluded from the adherence rating. In cases of
missing blood samples or concentrations not detectable
due to interferences, all available blood samples for the
patient were discussed with one of the authors with
long-standing expertise in therapeutic drug monitoring
(CH). Based on the course of available SER concentra-
tions, DSER concentrations and ratios DSER:SER, ad-
herence was estimated for these patients. If only one
blood sample was available, the patient was excluded
from the adherence rating. As high SER concentrations
(> 100 ng/ml) are often observed in case of concomitant
medication, SER concentrations above the target range
were considered adherent, if the corresponding ratio
DSER:SER fell into the target range.
In addition, a binary overall adherence rating was
employed distinguishing adherent from non-adherent
partially non-adherent patients for all randomized pa-
tients and all ITT patients, respectively.For the SER group, we also aimed at identifying overt
and hidden forms of non-adherence. Non-adherence was
considered overt, if patients chose to discontinue or refuse
SER treatment or withdrew informed consent during the
short-term phase of the trial for randomized patients and
during the whole trial phase for ITT patients, respectively.




Initially, the power calculation was based on expected dif-
ferences in the percentage of patients with 1% improve-
ment in HbA1c levels in both treatment groups. As the
primary outcome variable was changed into a continuous
variable due to an amendment to the protocol in Novem-
ber 2008, the power calculation was changed as follows:
The power calculation was based on expected differences
in HbA1c levels of the comparison groups in the (ITT)
sample. This sample consisted of all randomized patients
who entered the 12-month follow-up phase. Considering
RCTs in which CBT [58] or SSRIs [59] were evaluated, a
treatment difference of 1.0% HbA1c could be assumed as
relevant. Standard deviations of HbA1c values of 1.42 and
1.8 were observed in these studies. For the current trial a
standard deviation of slightly more than 1.4 could be
expected. However, a standard deviation of 1.6 as a con-
servative approach was taken. Therefore, with 2×46
evaluable subjects, the trial will have 85% power to detect
a treatment difference of 1.0% HbA1c by means of a t-test
on a two-sided level of significance α = 0.05. Assuming a
drop-out rate of 60%, 230 (2×115) subjects had to be
randomized.
Analyses will be performed using an intent-to-treat
principle. However, if in the short-term phase dropout
rates in the two treatment groups differ by more than
10%, the primary analysis will employ all randomized
patients. This would be done because the comparison of
long-term treatment effects on glycemic control in pa-
tients who have an initial short-term improvement of
depressive disorder (HAMD reduction ≥ 50% or HAMD
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dropout rates in the short-term phase are similar.
Analysis of outcome variables
No interim analyses are planned. The primary outcome
of the trial ‘change of glycemic control’ is defined as the
difference in HbA1c value from baseline to the end of
the long-term phase compared for the different treat-
ment groups using an analysis of covariance (ANCOVA)
controlling for baseline HbA1c value and baseline
HAMD score. The primary analysis will be focused on
observed cases. The analysis will be repeated after
employing the last observation carried forward method
for missing HbA1c and HAMD scores. An appropriate
method has to be chosen on an individual basis when
the missing value pattern becomes known. If more than
10% but less than 40% of the values are missing, mul-
tiple imputation methods will be considered.
The main secondary analysis is based on the num-
bers and proportions of patients who demonstrate im-
provement of glycemic control (≥ 1% improvement in
HbA1c values from baseline to the end of the long-
term phase). Differences between treatment groups
will be tested using logistic regression analysis
controlling for baseline HbA1c value and baseline
HAMD-score. Further secondary outcomes such as re-
mission of depression and improvement of depression will
be analyzed using logistic regression analysis controlling
for baseline HbA1c value and baseline HAMD score to
evaluate treatment effects. Differences between treatment
groups in improvement in HrQoL (SF-36 mental and
physical component scores) and improvement of diabetes
related distress (as assessed by PAID) will be analyzed
using analyses of covariance controlling for baseline
HbA1c values and baseline SF-36 scores (mental and ac-
cordingly physical component score) or baseline PAID
scores, respectively.
All primary and secondary analyses will be repeated con-
trolling for potential confounders. To identify confounders
such as age, sex, coordinating institution, diabetes type,
diabetes complications, education years, income, single/
recurrent episode(s) and comorbidity with other mental
disorders, a correlation analysis will be employed. Baseline-
variables associated (p < .10) with long-term outcome vari-
ables (HbA1c, HAMD score, SF-36 component scores and
PAID score, respectively) will then be included as further
control variables.
According to the intent-to-treat principle all analyses
will be conducted for the ITT population. The analyses
for safety population, randomized population and per
protocol population will be considered as secondary.
An exploratory subgroup analysis for type of diabetes
will be employed for the primary outcome. Therefore, the
primary analysis will be repeated including an interactionterm of diabetes type and treatment group in the
ANCOVA. Further covariates will be baseline HbA1c and
baseline HAMD score. For remission of depression from
the end of the short-term phase to the end of follow-up a
logistic regression including an interaction term of dia-
betes type and treatment group, baseline HbA1c and base-
line HAMD score will be performed, respectively. These
analyses have to be considered exploratory.
Adherence to treatment will be displayed descriptively
overall and for each treatment group. Differences in ad-
herence between both treatment groups will be analyzed
using chi-square tests. An exploratory subgroup analysis
for adherence groups will be employed for change in
HbA1c from the end of short-term phase to the end of the
follow-up. Therefore, an ANCOVA will be performed in-
cluding an interaction term of adherence group and treat-
ment group. Further covariates will be HbA1c and HAMD
score at the end of the short-term phase. For remission of
depression from the end of the short-term phase to the
end of follow-up a logistic regression including an inter-
action term of adherence group and treatment group,
HbA1c and HAMD score at the end of short-term phase
will be performed, respectively. These analyses have to be
considered exploratory, as the statistical power might not
be sufficient.
Further exploratory secondary analyses will be per-
formed such as the analysis, whether improvement in de-
pression shows a stronger association with better HbA1c
in the CBT group than in the on-going medication group;
and, if this is the case, to test, if the degree of diabetes
self-care will increase more in the CBT group than in the
on-going medication group (see Additional file 6 ‘Detailed
statistical analysis plan’).
Quality assurance
Safety Differences between treatment groups regarding
rates of adverse events such newly emerging tendency
will be displayed descriptively. Numbers and percentages
of adverse events and number and percentage of sub-
jects with adverse events will be presented for each oc-
curring system organ class and for each preferred term
within system organ class by treatment group and with a
total column. Additionally, this will be done for relation-
ship, intensity and seriousness of adverse events. The
results will be displayed for the safety population (see
Additional file 5 ‘Safety manual’ (in German); and ‘Defi-
nitions and assessment of adverse events’).
Data management A data management plan (DMP)
was established for the DAD study to specify each data
management process for the DAD trial. The purpose of
the DMP is to describe the underlying data management
process which governs collection, management, review
and reporting of data from this clinical trial. The content
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data management procedures including data collection
and data flow and the Data Validation Plan. The DMP
documents the validation strategy and tools, and refer-
ences responsibilities for different tasks. All data manage-
ment activities were performed according to the current
Standard Operating Procedures (SOPs) of the IZKS (see
Additional file 7 ‘Data management plan’).
Monitoring Clinical on-site monitoring was performed
by personal visits from a clinical monitor according to
SOPs of the IZKS. To initiate the study, the monitor vis-
ited each participating local trial site and coordinating
study centers. The monitors ensured that the investiga-
tors and their staff understand all requirements of the
protocol and their regulatory responsibilities. Each site
was visited by the monitor at regular intervals to ensure
compliance with the study protocol, GCP and legal
aspects. The monitors reviewed the entries into the Case
Report Forms (CRF) on the basis of the source docu-
ments. The presence of correct informed consents was
checked for every patient. Source document verification
(SDV) was performed for 100% of core data (randomi-
zation, primary endpoint and SAE) and 20% of other
data in this study. Details were specified in the monito-
ring manual for the DAD study. The investigators had to
allow the monitor to look at all relevant documents and
were requested to provide support at all times to the
monitor. By frequent communications (letters, telephone,
fax), the monitors ensured that the trial was conducted
according to the protocol and regulatory requirements.
Advisory board An independent scientific advisory board
was established to supervise the conduct of the trial and
to issue recommendations for early termination, modifica-
tions or continuation of the trial, if necessary.
Members of the Advisory Board are:
– Prof. Dr. Ulrich Hegerl, Clinic and Policlinic of
Psychiatry and Psychotherapy of the University of
Leipzig, Germany.
– Prof. Dr. Walter Lehmacher, (Institute for Medical
Statistics, Informatics and Epidemiology of the
University of Cologne, Germany.
– Prof. Dr. Martin Hautzinger, Eberhard-Karls
-University, Institute of Psychology, Department of
Clinical and Developmental Psychology, Tuebingen,
Germany.
Ethical aspects
The procedures set out in the trial protocol regarding
the conduct, evaluation, and documentation of this trial
are designed to ensure that all persons involved in the
trial abide by Good Clinical Practice (GCP) and theethical principles described in the current revision of the
Declaration of Helsinki. Clinical monitoring, data man-
agement, pharmacovigilance, regulatory affairs and bi-
ometry according to GCP were conducted by the IZKS
Mainz. The trial was carried out in keeping with local legal
and regulatory requirements. The requirements of the
AMG, the GCP regulation, and the Federal Data Protec-
tion Law (BDSG) have been kept. The trial was approved
by Medical Ethics Committee Hessen (Ethikkommission
der Landesärztekammer Hessen no. 2/2006) on 14/03/
2006. The Federal Institute for Drugs and Medical De-
vices approved the trial on 17/03/2006. Three substantial
amendments have been approved by both institutions in
August 2006, April 2007 and November 2008. All patients
were in treatment, regularly seen by diabetologists and
psychologists. Before being admitted to the clinical trial,
the patients agreed to participate after the nature, scope,
and possible consequences of the trial have been explained
in a form understandable to them. The patients gave writ-
ten informed consent and received a copy of the signed
consent document. The documents were in language that
was understandable to the patients and specified who in-
formed them. During the trial, patients were identified
solely by means of year of birth and an individual identifi-
cation code (patient number, randomization number).
Discussion
Despite the increasing number of studies evaluating
treatment options for depression in diabetes, the evi-
dence for the identification of a single treatment, which
could significantly improve psychological outcomes and
glycemic control at the same time remains inconclusive
[17,18]. Furthermore, as pointed out by Markowietz and
colleagues [60], most interventions were not designed to
directly improve diabetes self-care and did not evaluate
effects on further outcome variables such as quality of
life or remission of depression. The current trial attempts
to address these limitations by including only patients
with poor glycemic control (HbA1c > 7.5%), developing a
cognitive behavioral therapy covering diabetes-specific
aspects such as goal-setting to enhance diabetes-self-care,
and by assessment of further outcome variables such
as remission of depression, improvement in quality of
life and reduction of diabetes-related distress. As was
observed in the most recent systematic review on this
topic the quality of the trials in this field is very heteroge-
neous and especially active comparison trials are rare [18].
Therefore, we conducted this trial comparing for the first
time the efficacy of a psychological treatment to psycho-
pharmacological treatment for depression in patients with
depression with a strong emphasis on sound metho-
dology. Thus, we think that the DAD study will add im-
portant knowledge to the field of depression treatment in
diabetes.
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The trial commenced in April 2006, and patient recruit-
ment was completed in May 2009, resulting in a sample
of 251 randomized patients. After reaching the cal-
culated sample size of 230 patients, all patients already
under screening have been randomized additionally.
Currently we are in the analysis phase.
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